Peripheral Artery Disease - Global Strategic Business Report

The global market for Peripheral Artery Disease was valued at US$4.1 Billion in 2025 and is projected to reach US$6.8 Billion by 2032, growing at a CAGR of 7.3% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Peripheral Artery Disease Market - Key Trends & Drivers Summarized

Why Is Peripheral Artery Disease Gaining Attention as a Major Global Cardiovascular Health Concern?

Peripheral Artery Disease (PAD), characterized by the narrowing or blockage of arteries - primarily in the lower extremities - due to atherosclerotic plaque buildup, is increasingly being recognized as a critical global health issue. Affecting over 200 million people worldwide, PAD not only impairs mobility and quality of life but also significantly elevates the risk of myocardial infarction, stroke, and limb amputation. Its growing prevalence, particularly among aging populations, diabetics, and smokers, underscores the need for early diagnosis, aggressive risk factor management, and accessible treatment options.

What makes PAD particularly challenging is its underdiagnosis and frequent misidentification as a symptom of aging or arthritis, leading to delayed interventions. As public awareness increases and screening protocols improve, the demand for diagnostic imaging, vascular assessments, and minimally invasive therapies is accelerating. Health systems worldwide are now integrating PAD detection into routine cardiovascular care and diabetes management programs, propelling clinical focus and therapeutic innovation aimed at reducing complications and improving long-term vascular outcomes.

How Are Therapeutic Advances and Minimally Invasive Devices Shaping PAD Management?

Modern PAD treatment is moving beyond systemic pharmacotherapy to include advanced endovascular interventions and biologically engineered therapeutic strategies. Antiplatelet agents, lipid-lowering drugs, and antihypertensives remain foundational in risk mitigation. However, device-based interventions such as balloon angioplasty, drug-eluting stents (DES), atherectomy systems, and drug-coated balloons (DCBs) are being increasingly adopted for revascularization, especially in patients with lifestyle-limiting claudication or critical limb ischemia (CLI).

Technological innovation is enhancing device design with features like ultrathin strut platforms, bioresorbable polymers, and targeted drug release mechanisms to reduce restenosis and improve vessel patency. Adjunctive tools such as intravascular ultrasound (IVUS), optical coherence tomography (OCT), and perfusion imaging are improving procedural accuracy and post-operative monitoring. Meanwhile, regenerative therapies involving autologous stem cells and angiogenic growth factors are under clinical evaluation for complex and non-reconstructable PAD cases. These advancements are shifting the treatment paradigm toward personalized, limb-salvaging, and less invasive management.

Which Risk Groups and Global Health Systems Are Driving Demand for PAD Diagnostics and Interventions?

PAD is most prevalent among individuals over 65, smokers, patients with diabetes mellitus, hypertension, dyslipidemia, and chronic kidney disease. The growing burden of noncommunicable diseases and sedentary lifestyles in urban populations is pushing PAD further into public health focus. Veterans, amputees, and post-operative patients also form significant segments requiring vascular monitoring and rehabilitative care. As multidisciplinary care models expand, PAD is increasingly managed in collaboration with cardiologists, diabetologists, vascular surgeons, and primary care providers.

North America and Western Europe lead the market in terms of diagnosis and intervention rates, owing to structured vascular programs, reimbursement coverage, and widespread access to endovascular labs. However, Asia-Pacific - particularly China, India, and Japan - is witnessing the fastest growth in PAD interventions due to demographic shifts, rising diabetes prevalence, and improving healthcare infrastructure. Public health agencies in Latin America and Africa are beginning to recognize PAD as a target for noncommunicable disease strategies, driving investments in screening campaigns, training, and device accessibility.

What Is Driving Long-Term Growth and Strategic Innovation in the PAD Treatment Market?

The growth in the peripheral artery disease market is driven by a convergence of aging demographics, rising comorbidity rates, and innovations in both pharmaceutical and interventional therapies. As PAD gains recognition as a systemic vascular disorder with far-reaching consequences, healthcare stakeholders are increasingly prioritizing early detection, long-term surveillance, and cost-effective interventions. Patient engagement platforms, telemonitoring, and wearable diagnostics are also being integrated into PAD management to improve adherence and remote tracking.

Strategically, companies are developing next-generation drug-device combinations, bioabsorbable implants, and AI-powered imaging tools to optimize procedural outcomes and reduce recurrence. Partnerships between medtech firms, academic institutions, and public health bodies are fostering clinical trials and health economic studies to validate emerging therapies. As value-based care models emphasize quality-adjusted life years (QALYs) and limb salvage outcomes, the PAD market is expected to continue its trajectory as a key focus within the broader cardiovascular therapeutics landscape.

Report Scope

The report analyzes the Peripheral Artery Disease market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Product Type (Devices, Drugs); End-User (Specialty Clinics, Hospitals).
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Devices segment, which is expected to reach US$4.6 Billion by 2032 with a CAGR of a 8.5%. The Drugs segment is also set to grow at 5.1% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $1.3 Billion in 2025, and China, forecasted to grow at an impressive 11.7% CAGR to reach $1.7 Billion by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Peripheral Artery Disease Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Peripheral Artery Disease Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Peripheral Artery Disease Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, AngioDynamics, B. Braun Melsungen AG, Bayer AG, Becton, Dickinson and Company and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Peripheral Artery Disease market report include:

• Abbott Laboratories
• AngioDynamics
• B. Braun Melsungen AG
• Bayer AG
• Becton, Dickinson and Company
• Biotronik
• Boston Scientific Corporation
• Cardinal Health
• Cook Medical
• Cordis
• Endologix, Inc.
• Johnson & Johnson MedTech
• LeMaitre Vascular
• Medtronic plc
• Merit Medical Systems
• OrbusNeich
• Philips Healthcare
• Shockwave Medical
• Straub Medical AG
• Terumo Corporation

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, our reports extend market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.